Innoviva, Inc. (INVA) Stock Analysis

Q: What is the INVA stock price target?

Take-profit $28.88 (+24.0% upside). Target $28.88 (+23.9%), stop $22.09 (−5.5%), A.R:R 4.7:1.

Q: Is INVA overvalued or undervalued?

Innoviva, Inc. trades at a P/E of 7.0 (forward 10.4). TrendMatrix value score: 8.6/10. Overall verdict: Hold.

Q: What do analysts say about INVA?

11 analysts cover INVA with a consensus score of 4.1/5. Average price target: $33.

Temp Headwind edge

HoldModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $23.30, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings in 6 days (event risk).

Innoviva is a diversified biopharmaceutical company with a royalty portfolio from GSK partnerships (RELVAR/BREO ELLIPTA and ANORO ELLIPTA for COPD/asthma) plus an infectious disease commercial platform (GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE). Near-term revenues are... Read more

$23.30+24.0% A.UpsideScore 6.6/10#6 of 158 Biotechnology

Stop $22.09Target $28.88(analyst − 13%)A.R:R 4.7:1

Analyst target$33.20+42.5%5 analysts

$28.88our TP

$23.30price

$33.20mean

$18

$46

Hold if already holding. Not a fresh buy at $23.30, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Deep value: 53% margin of safety. Extreme undervaluation. | News modifier -2 (STRONG_BUY_NOW → HOLD_IF_HOLDING) Score 6.6/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

High-quality business

Attractive valuation

Strong growth profile

Risks

Concentration risk — Counterparty: GSK

Earnings in 6 days (event risk)

Consecutive earnings misses (2)

Key Metrics

P/E (TTM)7.0

P/E (Fwd)10.4

Mkt Cap$1.7B

EV/EBITDA7.5

Profit Mgn65.9%

ROE29.1%

Rev Growth24.8%

Beta0.40

DividendNone

Rating analysts11

Quality Signals

Piotroski F8/9

Options Flow

P/C0.46bullish

IV101%elevated

Max Pain$18-24.9% vs spot

Concentration Risks(10-K Item 1A)

HIGHcounterpartyGSK
10-K Item 1A: 'currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK's ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·2 ceiling hits

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value8.615%1.29

Quality7.615%1.14

Growth8.715%1.30

Momentum2.810%0.28

Sentiment6.410%0.64

Insider Activity5.010%0.50

Peer Rank5.910%0.59

Technical Setup7.55%0.38

Risk Profile5.45%0.27

Catalyst4.85%0.24

Overall (Σ contributions)6.63

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.0

Obv

1.0

Macd

1.7

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.8<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 4.7 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

44 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $22.75Resistance $24.45

Price Targets

$22

$29

A.Upside+23.9%

A.R:R4.7:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! NEWS_MOD=-2: STRONG_BUY_NOW → HOLD_IF_HOLDING

! Momentum score 2.8/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:6d<=7d

Earnings

2/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is INVA stock a buy right now?

Hold if already holding. Not a fresh buy at $23.30, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Deep value: 53% margin of safety. Extreme undervaluation. | News modifier -2 (STRONG_BUY_NOW → HOLD_IF_HOLDING) Target $28.88 (+23.9%), stop $22.09 (−5.5%), A.R:R 4.7:1. Score 6.6/10, moderate confidence.

What is the INVA stock price target?

Take-profit target: $28.88 (+24.0% upside). Target $28.88 (+23.9%), stop $22.09 (−5.5%), A.R:R 4.7:1. Stop-loss: $22.09.

What are the risks of investing in INVA?

Concentration risk — Counterparty: GSK; Earnings in 6 days (event risk); Consecutive earnings misses (2).

Is INVA overvalued or undervalued?

Innoviva, Inc. trades at a P/E of 7.0 (forward 10.4). TrendMatrix value score: 8.6/10. Verdict: Hold.

What do analysts say about INVA?

11 analysts cover INVA with a consensus score of 4.1/5. Average price target: $33.

What does Innoviva, Inc. do?Innoviva is a diversified biopharmaceutical company with a royalty portfolio from GSK partnerships (RELVAR/BREO ELLIPTA...